# (19) World Intellectual Property Organization International Bureau



# 

### (43) International Publication Date 8 September 2000 (08.09.2000)

**PCT** 

# (10) International Publication Number WO 00/51589 A3

(51) International Patent Classification<sup>7</sup>: A61K 31/365, A61P 35/00, 35/04, 15/08, 19/10

(21) International Application Number: PCT/US00/05582

(22) International Filing Date: 3 March 2000 (03.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/122,953 5 March 1999 (05.03.1999) US 60/169,564 8 December 1999 (08.12.1999) US

(71) Applicant (for all designated States except US): THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): BOYD, Michael, R. [US/US]; 5217 Fairgreene Way, Ijamsville, MD 21754 (US).

(74) Agents: LARCHER, Carol et al.; Leydig, Voit & Mayer, Ltd., Suite 4900, Two Prudential Plaza, 180 North Stetson, Chicago, IL 60601-6780 (US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


#### **Published:**

With international search report.

(88) Date of publication of the international search report: 12 July 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: VACUOLAR-TYPE (H+)-ATPase-INHIBITING COMPOUNDS, COMPOSITIONS, AND USES THEREOF



(57) Abstract: The present invention provides vacuolar-type (H+)-AT-Pase-inhibiting compounds, compositions thereof, and methods of using them to treat or prevent a condition treatable by the inhibition of a vacuolar-type (H+)-ATPase. The composition of the present invention comprises a compound of the present invention and a carrier. The method of the present invention includes administering a vacuolar-type (H+)-AT-Pase inhibiting-effective amount of a compound of the present invention. The compound of the present invention has formula (I) wherein R¹ and R² are H, saturated or unsaturated alkyl, aryl, R6CH2-, R6CO-, or R6SO2-, wherein R6 is H, saturated or unsaturated alkyl, or aryl; R³ is H, alkyl, aryl, an oxime, or an oxime methyl ether; the aromatic ring is unsubstituted or substituted; and Z is a contiguous linker comprising a chain of 0-10 atoms which, together with the five atoms beginning with the carbon of the aromatic ring in meta-relationship with OR¹ and end-

ing with the carbon directly attached to the alkyl oxygen of the lactone, integrally form a 5-17 membered ring; or a pharmaceutically acceptable salt, an ester, or a prodrug thereof.

WO 00/51589 A3

### INTERNATIONAL SEARCH REPORT

nal Application No PCT/US 00/05582

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/365 A61P35/00 A61P15/08 A61P19/10 A61P35/04 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Category 6 χ GALINIS L DEBORAH ET AL: "Lobatamides A 1,17,19, 35 and B. Novel Cytotoxic Macrolides from the Tunicate Aplidium lobatum" JOURNAL OF ORGANIC CHEMISTRY, US, AMERICAN CHEMICAL SOCIETY. EASTON, vol. 62, no. 26, 1997, pages 8968-8969, XP002111864 ISSN: 0022-3263 page 8968, left-hand column -/--Further documents are listed in the continuation of box C. Patent family members are listed in annex. Χ ° Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but \*A\* document defining the general state of the art which is not considered to be of particular relevance cited to understand the principle or theory underlying the invention \*E\* earlier document but published on or after the international "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the citation or other special reason (as specified) document is combined with one or more other such docu-ments, such combination being obvious to a person skilled \*O\* document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 21/12/2000 8 December 2000 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 European Falenti Olitice, F.B. 56 16 Falentia. NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016

3

Voyiazoglou, D

## INTERNATIONAL SEARCH REPORT

Inter onal Application No PCT/US 00/05582

		PC1/US 00/05582								
C.(Continu	C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT									
Category °	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.								
Х	ERICKSON L ET AL: "Salicylihalamides A and B, Novel Cytotoxic Macrolides form the Marine Sponge Haliclona sp" JOURNAL OF ORGANIC CHEMISTRY, US, AMERICAN CHEMICAL SOCIETY. EASTON, vol. 62, no. 23, 1997, pages 8188-8192, XP002111863 ISSN: 0022-3263 page 8191, left-hand column; examples 1,2	1,17,19, 35								
X	WO 99 05136 A (PANNELL LEWIS ;BEUTLER JOHN A (US); BOYD MICHAEL R (US); ERICKSON) 4 February 1999 (1999-02-04) cited in the application claims 1,7,18	1,17,19, 35								
X	K. A. DEKKER ET AL: "Novel lactone compounds from Morterella verticillata that induce the human low density lipoprotein receptor gene: fermentation, isolation, structural elucidation and biological activities" JOURNAL OF ANTIBIOTICS., vol. 51, no. 1, 1998, pages 14-20, XP000971100 JAPAN ANTIBIOTICS RESEARCH ASSOCIATION. TOKYO., JP ISSN: 0021-8820 cited in the application page 14, left-hand column; figure 1	1,19								
X	JIN WOO KIM ET AL: "Oximidines I and II: Novel antitumor macrolides from Pseudomonas sp." JOURNAL OF ORGANIC CHEMISTRY., vol. 64, no. 1, 1999, pages 153-155, XP000971102 AMERICAN CHEMICAL SOCIETY. EASTON., US ISSN: 0022-3263 cited in the application page 153, left-hand column, line 1 - line 7; figure 1	1,17,19, 35								
Α	KEN-ICHI SUZUMURA ET AL: "Structural elucidation of YM-75518, a novel antifungal antibiotic isolated from Pseudomonas sp.Q38009" TETRAHEDRON LETTERS, vol. 38, no. 43, 1997, pages 7573-7576, XP002154892 OXFORD GB figure 1	1,17,19, 35								

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-11,19-29

Present claims 1-11,19-29 relate to a method and composition defined by reference to the following term: vacuolar-type (H+)-ATPase The use of this term in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is impossible to compare the parameters the applicant has chosen to employ with what is set out in the prior art. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, the search has been restricted to the parts relating to the method and composition mentioned in the description at pages 20-21.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

information on patent family members

Inter. nal Application No
PCT/US 00/05582

						PCT/US 0	10/05582
Pa cited	tent document in search report		Publication P. date r				Publication date
WO	9905136	Α	04-02-1999	AU EP	850159 100009	98 A 53 A	16-02-1999 17-05-2000